WuXi Biologics boosts payload-linkers agreements amid strong ADC demand

WuXi Biologics (Cayman) Inc. has revised the annual cap for its 2023 Payload-Linkers Master Services Agreement, increasing it from RMB168.0 million to RMB200.0 million for the year ending December 31, 2025. This adjustment is driven by XDC Group's strong performance, anticipated business growth, and increased demand for ADC CRDMO services in the second half of 2025. Historical transaction amounts for Payload-linkers Services were RMB142.6 million for the year ended December 31, 2024, and RMB56.5 million for the six months ended June 30, 2025.

Additionally, XDC Group is proposing to enter into the 2026 Payload-Linkers Master Services Agreement to renew the services for a further three years, effective January 1, 2026, to December 31, 2028. The proposed annual caps for this new agreement are RMB300.0 million for 2026, RMB400.0 million for 2027, and RMB400.0 million for 2028. These caps reflect historical transaction volumes, expected business growth, and increased manufacturing capacity.